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Abstract
Background Medication communication and prescribing on the post-take ward round following patient admission to hospital 
can be suboptimal leading to worse patient outcomes. Objective To evaluate the impact of clinical pharmacist participation on 
the post-take ward round on the appropriateness of medication prescribing, medication communication, and overall patient 
health care outcomes. Setting Tertiary referral teaching hospital, Brisbane, Australia. Method A pre-post intervention study 
was undertaken that compared the addition of a senior clinical pharmacist attending the post-take ward was compared to 
usual wardbase pharmacist service, with no pharmacist present of the post-take ward round. We assessed the proportion 
of patients with an improvement in medication appropriateness from admission to discharge, using the START/STOPP 
checklists. Medication communication was assessed by the mean number of brief and in-depth discussions, with health 
care outcomes measured by comparing length of stay and 28-day readmission rates. Main outcome measures: Medication 
appropriateness according to the START/STOPP list, number and type of discussions with team members and length of stay 
and readmission rate. Results Two hundred and sixty patients were recruited (130 pre- and 130-post-intervention), across 
23 and 20 post-take ward rounds, respectively. Post-intervention, there was increase in the proportion of patients who had 
an improvement medication appropriateness (pre-intervention 25.4%, post-intervention 36.9%; p = 0.004), the number of 
in-depth discussions about patients’ medication (1.9 ± 1.7 per patient pre-intervention, 2.7 ± 1.7 per patient post-, p < 0.001), 
and the number relating to high-risk medications (0.71 ± 1.1 per patient pre-intervention, to 1.2 ± 1.2 per patient post-, 
p < 0.05). Length of stay and 28-day mortality were unchanged. Conclusion Clinical pharmacist participation on the post-
take ward round leads to improved medication-related communication and improved medication appropriateness but did not 
significantly improve health care outcomes.
Keywords Australia · Communication · Medication safety · Prescribing · Team work · Ward round
Impacts on practice
• Pharmacist input to medical officers decision making 
during a patients’ admission can improve the appropri-
ateness of medications for patients.
• Clinical pharmacists input improves the collaborative 
optimisation of medication use. The involvement of a 
pharmacist can ensure increased communication about 
medications during the admission process and that deci-
sions made by medical staff around medication prescrib-
ing are enacted upon.
• This model of care ensures the efficient use of all mem-
bers of the healthcare team by ensuring pharmacists input 
to optimising medicines in conjunction with senior medi-
cal staff. Although this study was not powered to show 
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impacts on patient health care outcomes (such as length 
of stay and unplanned readmissions), the addition of a 
pharmacist on the post take ward round ensures more 
appropriate medication use, which is essential for an 
ageing population with complex conditions and a high 
medication burden.
Introduction
Poor prescribing leads to patient harm through increased 
medication errors and adverse drug events (ADEs) [1]. Inter-
ventions by clinical pharmacists are known to improve the 
safety and quality of prescribing [2–5], with most interven-
tions occurring independent of the ward round [6, 7]. In 
Australia, the duties of hospital based clinical pharmacists 
working on hospital wards includes medication reconcilia-
tion, clinical review and overall contribution to the medi-
cines management pathway in order to minimise the risks 
associated with the use of medicines and to optimise the use 
of medicines [6].
In many Australian public hospitals, patients are initially 
seen by junior medical staff on admission who undertake 
assessment and institute preliminary management plans. The 
patient is then presented to the treating consultant on a ward 
round often termed the “post-take ward round” (PTWR), 
which usually occurs on the day of or day after presenta-
tion. On the PTWR the treating consultant will often make 
diagnoses, refine management plans and begin attempts to 
optimise the patient’s pharmacotherapy [8]. The PTWR 
is usually only attended by senior (consultant) and junior 
medical staff (resident and registrar, sometimes referred to 
as house officers). Our initial study of medication commu-
nication on the PTWR without a pharmacist present found 
that the level of medication communication and implemen-
tation of agreed medication-related management decisions 
was suboptimal [9].
Pharmacist participation on ward rounds influences the 
quality of prescribing and may lead to better outcomes than 
pharmacist interventions at other times [10, 11] with prior 
studies identifying improved rates of prescribing errors and 
preventable ADEs [7, 12, 13]. However, there is limited evi-
dence of benefits of a pharmacist attending the PTWR. A 
study by Fertleman et al. [2] showed that a pharmacist on 
a general medical PTWR, in comparison to normal prac-
tice whereby pharmacist input occurred after the PTWR, 
resulted in improved accuracy of drug history documenta-
tion, reduced prescribing costs and a decrease in potential 
medication risk to the patient. However, this was a small 
study (103 patients) and used a single intervention pharma-
cist which potentially limits the generalisability of results. 
Additionally, the degree of communication between senior 
and junior medical staff and pharmacists was not specifically 
investigated nor was medication appropriateness assessed.
Aim of the study
We aimed to evaluate the impact of clinical pharmacist par-
ticipation on the PTWR on medication prescribing as meas-
ured by medication appropriateness, the level and extent of 
medication communication and patient and service delivery 
related outcomes, including length of stay.
Ethics approval
Ethics approval was obtained from the Hospital and Uni-
versity Human Research Ethics Committees (HREC/13/
QRBW/443;2014000705). Verbal consent was obtained and 
recorded for all patients and written consent was obtained 
from all pharmacists and medical staff prior to the period of 
observation. Consent could be withdrawn at any time.
Method
Study design
The study occurred in the Internal Medicine Department at 
a 929-bed quaternary and tertiary referral teaching hospital 
in Brisbane, Australia. The study was a pre-post interven-
tion trial, with the initial observation period (comparator 
group) occurring over 6-weeks between April and June 
2014. The comparator group consisted of usual medical care 
that included daily ward pharmacist review (including within 
24 h of admission) on weekdays, with no pharmacist present 
on the PTWR. The intervention period occurred during a 
six-week period between August and October 2014 (inter-
vention group). The intervention consisted of, in addition to 
usual medical care, a senior clinical pharmacist participat-
ing in the PTWR team (see Fig. 1). One of four pharmacists 
participated, each having a minimum of 6 years of clinical 
pharmacy experience, employed at a senior pharmacist level 
and had recently demonstrated a consistent level of com-
petent ward-based performance measured using a clinical 
competency assessment tool [6]. The lead researcher briefed 
each of the pharmacists regarding their role and the expected 
level of interaction on the PTWR.
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Participants and data collection
Patients (18 years or older) under the care of all eight of 
the hospital’s internal medical teams were observed in 
both study phases. Inpatient medication order forms, the 
Discharge Medication Record (DMR) and medical records 
were used to collect data before the PTWR and on hospi-
tal discharge. The PTWR would start at 8 am and patients 
were included in the study if they were seen between 8 and 
11 am for pragmatic reasons (availability of the research 
pharmacist). Patients seen during this time were thought to 
be a representative sample of the patients admitted over-
all as generally the team would review the patients starting 
with those most recently admitted as those were the patients 
admitted by the medical officer working overnight, allowing 
that medical officer to hand over patients and complete their 
shift in a timely manner. Although not random sampling, 
the same method of patient inclusion occurred in both the 
comparator and intervention groups.
One experienced pharmacist observed discussion related 
to individual patients for both groups. The observer did 
not participate in any discussions or prescribing decisions 
unless there was a need to intervene to prevent or highlight a 
potential adverse event that had so far not been realised and 
may cause immediate harm. Patient demographic informa-
tion, reason for admission classified according to diagnosis 
related group (DRG), medical co-morbidities, details of staff 
present on PTWR, the total time for each patient consulta-
tion, medications on admission and discharge, evidence of 
inpatient clinical pharmacy review, discussion of previous 
allergy/ADR history and data on completion and provision 
of DMR were collected using a structured form. All medica-
tions were classified according to the anatomical therapeutic 
chemical (ATC) classification system.
Any mention of medication was recorded as medication 
related communication and was used to assess the frequency 
and depth of medication-related discussions. If there was a 
two-way discussion between medical staff and/or the phar-
macist with the intention of the discussion as to whether 
a treatment modification was required, this was classified 
an in-depth discussion. If there was no two-way discussion, 
rather a brief mention of the medication by one person, this 
was classified as brief medication discussion (e.g., if a medi-
cation list was read out and there was no further discussion). 
Each medication was categorised as high risk (antibiotics, 
potassium, insulin and other hypoglycaemic agents, narcot-
ics and other sedatives, chemotherapy and heparin and other 
anticoagulants) or non-high risk of medication related harm 
according to the Australian Safety and Quality Council’s 
APINCH classification system [14]. Further, for all medica-
tion-related discussions, it was assessed as to whether any 
proposed treatment modification was properly actioned (i.e., 
the change agreed upon during discussions was actioned).
In addition to investigating medication related discussion, 
medication appropriateness was assessed using the START/
STOPP tools, with the START checklist a validated register 
of medications that may be appropriate to initiate, while 
the STOPP list identifies potentially inappropriate prescrib-
ing [15]. The lead researcher applied each of the START/
STOPP criteria to the admission and discharge medications 
each patient was prescribed on the medication chart and 
using the patient medical history from the admission and 
discharge notes. If a patient was appropriately prescribed or 
de-prescribed a medication on these criteria lists, this would 
represent an improvement in medication appropriateness, 
with each indicator. A total score was given for each patient 
with the term score defined as the total number of flagged 
START/STOPP criteria. Each indicator was a yes/no and 
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Fig. 1  Flow chart of comparator and intervention phase of study
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counted as one point. If there were cases of multiple indi-
cators that applied to the same drug for a different reason, 
these were each counted as one. If there were multiple drugs 
which triggered the same indicator, this could only be scored 
once per indicator.
The START/STOPP tool was chosen due to its ease of 
use, inclusion of both potentially inappropriate medica-
tions and recommendations on medications which should 
be started, as it has been validated as an overall meas-
ure of medication appropriateness and is appropriate for 
the Australian setting [15, 16]. The START/STOPP tool 
was designed for use in patients 65 years or above and 
therefore the results in this patient subgroup were inde-
pendently investigated; however it was also applied to all 
study patients as many of the criteria may be applicable 
to all adult patients, there is evidence of association with 
adverse outcomes across wider patient groups and its use 
in all adults would tend to under- rather than overestimate 
any benefits seen in this study [17].
The occurrence of a ward based clinical pharmacy review 
was measured by evidence of either (1) a pharmacist signa-
ture indicating a medication review had been completed and/
or (2) the completion of a medication action plan (MAP), 
which is a document completed by a pharmacist during a 
medication review. Hospital related reporting data was col-
lected retrospectively from hospital administration.
Outcome measures
Primary outcome The difference in proportion of patients 
with an improvement in medication appropriateness from 
admission to discharge, between the comparator and inter-
vention groups.
Secondary Outcomes The difference between the com-
parator and intervention groups for the following: 
• The mean change in START/STOPP score* counted pre-
PTWR and at discharge, with a pre-specified subgroup 
analysis of patients 65 years of age and older.
• Medication-related discussion on the PTWR (all discus-
sions, plus in-depth discussions), with a subgroup analy-
sis of high risk medications.
• For all in-depth medication related discussions, the dif-
ference in the number which were able to be actioned 
and that were actioned (i.e., led to a change in therapy) 
throughout the patients’ hospital stay.
• Patient and service delivery related outcomes:
• Duration of the PTWR (e.g., time spent by PTWR 
team with each patient).
• Ward based pharmacist activity.
• Length of hospital stay.
• Unplanned readmission to the same hospital at 
30 days.
Data analysis
It was difficult to undertake a valid sample size calculation 
given the scarcity of literature assessing the impact of a 
clinical pharmacist on PTWR on medication appropriate-
ness and therefore the sample size was based on pragmatism 
using the maximum time available for the research staff to 
be able to undertake data collection. However, we predicted, 
given these time constraints, that we would be able to recruit 
~ 125 patients in each group which is over double the size of 
the only other study to address a pharmacist on the PTWR 
[2, 3]. It was anticipated that, should significant results not 
be achieved with the sample, that these results could be used 
to estimate a sample size for a more definitive trial.
R commander version 3.2.4 (2016–03–10) was used for 
data analysis. Patient demographics and other continuous 
data are presented as mean ± standard deviation (or median 
and Inter quartile range where appropriate). Chi squared 
tests were used to compare differences in proportions. T tests 
were used to compare differences in means where data were 
normally distributed and nonparametric alternative (Wil-
coxon rank sum) were used where data were not normally 
distributed. Categorical and binary data have been expressed 
as counts and percentages of the total number of possible 
outcomes. Statistical significance was achieved if p < 0.05.
Table 1  Patient characteristics
Statistical tests: * Chi squared, † student’s T test
Comparator 
group (N = 130)
Intervention 
group (N = 130)
p Value
Gender (female) N (%) 61 (47%) 69 (53%) 0.32*
Age mean (± SD) 66 ± 19 63 ± 20 0.20†
Age > 65 N (%) 75 (58%) 67 (51.5%) 0.32*
Mean number of medications on admission, prior to 
PTWR mean, (SD)
8.9 ± 5 8.56 ± 4.47 0.54†
Mean number of medications on discharge mean, (SD) 8.2 ± 4.79 7.8 ± 5.07 0.03†
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Results
During the 6-week observation period, 23 PTWRs with 130 
patient consultations were observed in the comparator group 
and 20 PTWRs with 130 patient consultations in the inter-
vention group. The characteristics of the comparator and 
intervention groups are shown in Table 1.
There was no significant difference in the change in 
number of medications in the two groups from admission to 
discharge (mean reduction in baseline cohort − 0.69 ± 2.93, 
compared to comparator cohort 0.76 ± 3.71, p = 0.45).
Admission medications were similar across both groups 
according to their ATC classification, with the most com-
mon systems “Alimentary tract and metabolism” accounting 
for 23% of comparator and 24.7% of intervention admission 
medications, “cardiovascular system” accounting for 21.2% 
of comparator and 17.2% of intervention admission medica-
tions and “nervous system” accounting for 22.9% of com-
parator and 27% of intervention admission medications. The 
reasons for admission were also similar, with 60 individual 
DRG presentations in the comparator cohort: the most fre-
quent classifications being “respiratory infection or inflam-
mation” (10) and “chest pain” (7). In the intervention group, 
there were 70 individual DRG presentations with “syncope 
and collapse” (7) and “chest pain” (6) the most common. 
The DRG presentations seen are representative of a general 
medicine population.
There were no difference in the proportion of patients 
prescribed high-risk medications and the types and pro-
portion of each type of high-risk medications was similar 
between groups (e.g., “heparin and other anticoagulants” 
which made up 35.5% in the comparator group and 40.8% 
in the intervention group and “antibiotics” made up 35.5% 
of in-depth discussions in the comparator group and 33.7% 
in the intervention group).
Patient and medication communication
Table 2 shows the frequency of “in depth medication discus-
sions” and shows a statistically significant greater number 
of medication discussions that were “in-depth” discussions 
with a mean of and 2.7 per patient in the intervention group 
and 1.9 per patient in the comparator group (p < 0.05). The 
number of discussions relating to high-risk medications sig-
nificantly improved from a mean of 0.71 per comparator 
patient to 1.2 per intervention patient (p < 0.05).
When analysing the difference in APINCH classifica-
tions for the in-depth medication related discussions relat-
ing to high-risk medications, the proportional spread across 
APINCH categories showed no significant variation between 
the comparator and intervention group.
In line with the increased number of in-depth discus-
sions, there was a statistically significantly higher number 
of in depth discussions actioned in the intervention group, 
compared with comparator, both at the end of the PTWR, 
and at discharge. However when expressed as a proportion 
of those able to be actioned, there was no significant dif-
ference in the proportion of in-depth discussions actioned 
during the PTWR in comparator and intervention group and 
no difference in the proportion actioned during the inpatient 
stay (see Table 2).
Medication appropriateness (START/STOPP tool)
The overall proportion of patients who had an improvement 
in their START/STOPP scores was significantly higher for 
the intervention group with 48 patients (37%) compared to 
Table 2  Patient and medication details discussed
Statistical tests: * Chi squared, † student’s T-test
Comparator group 
N = 130 patients
Intervention group 
N = 130 patients
p Value
Communication re patients
Patients with any type of medication communication n (%) 126 (96.9%) 124 (95.4%) 0.52*
Number of patients with allergy/ADR history discussed n (%) 48 (36.9%) 43 (33%) 0.54*
Number of patients whose adherence was discussed n (%) 19 (14.6%) 14 (10.8%) 0.36*
Medication communication: in depth discussions
Number of patients who had an in-depth medication discussion for n (%) 100 (76.9%) 122 (93.8%) < 0.001*
Number of in-depth medication discussions n (mean, SD) 249 (1.9 ± 1.7/patient) 352 (2.7 ± 1.7/patient) < 0.001†
Number of in-depth medication discussions relating to high risk (APINCH) medica-
tions n (mean, SD)
92 (0.71 ± 1.1/patient) 156 (1.2 ± 1.2/patient) < 0.001†
Proportion of in-depth discussions (actionable) which were actioned during PTWR n 
(%)
154/194 (79.4%) 236/284 (83.1%) 0.30*
Proportion of in-depth discussions (actionable) which were actioned on PTWR or 
inpatient stay n (%)
178/194 (91.7%) 264/284 (92.9%) 0.62*
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33 patients (25%) in the comparator group (p = 0.004). There 
was a greater difference in the proportion of patients who 
had a START/STOPP score improvement for the sub-group 
of patients 65 years or older (intervention 42%, comparator 
23%, p = 0.014).
Figure 2 illustrates the change in START/STOPP scores 
between admission and discharge across the entire patient 
cohort with changes ranging from a decrease in 3 START/
STOPP criteria to an increase in 4 criteria. Figure 3 illus-
trates the frequency of START/STOPP changes for the 
patients over the age of 65 (Table 3).  
The mean change in START/STOPP scores between 
admission and discharge was significantly higher for the 
intervention group (0.43 ± 0.88) than for the comparator 
group (0.3 ± 0.87; p = 0.049). In patients 65 years or older, 
there was a greater improvement in medication appropriate-
ness in the intervention group (0.52 ± 0.99) compared with 
the comparator group (0.3 ± 0.87; p = 0.028), or an extra 22 
appropriate medications per 100 patient admissions.
Patient and service delivery related outcomes
The ward-based clinical pharmacy services including 
patients who had a ward pharmacist review, the number who 
had a Medication Action Plan documented and who had a 
DMR prepared on discharge, length of stay and readmission 
rates were similar in the comparator and intervention periods 
(see Table 4).
Discussion
When a clinical pharmacist participated in the PTWR there 
was greater medication communication and an increase in 
the level of medication appropriateness at discharge com-
pared to usual care. The mean change in medication appro-
priateness was small (improvement of 0.13 START/STOPP 
indicators per patient) however this is equivalent to 13 extra 
appropriate medications or the de-prescribing of 13 extra 
Fig. 2  Change in START/
STOPP scores: entire cohort
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potentially inappropriate medications per 100 patients. 
There was an extra 12% of patients had an improvement 
in medication appropriateness, which equates to a number 
needed-to-treat of just over eight. Significant differences 
were seen in all patients and in the subgroup of patients 
aged 65 years or older, where the START/STOPP tool has 
been validated (number needed-to-treat for an improvement 
of medication inappropriateness of just over five) [18].
The model of care enacted in the intervention group 
allowed direct pharmacist input to prescribing discussion 
and decisions with senior members of the medical team 
during the PTWR, compared with usual care when ward 
pharmacists liaise with more junior medical staff after the 
senior medical team have made their input. We suggest that 
this high-level interaction, which led to an increase in both 
superficial and in-depth discussions related to medications, 
both generally and to high-risk medications resulted in 
improvements in medication appropriateness. These find-
ings support the proposition by Fertleman et al. that clinical 
pharmacists influence decisions at the point of prescribing 
[2] and the evidence from Leape and Scarsi that pharmacist 
interventions can lead to reduced medication related errors 
ADEs [2].
Reassuringly, the presence of the pharmacist did not 
prolong the time spent with each patient. The time spent 
by the PTWR team with each patient across both study 
cohorts was longer than the average found in a study by 
Herring et al. [19] which found an average time per patient 
of 12 min (10 min on routine rounds and 14 min on post-
take rounds).
There were a significantly higher absolute number of 
in-depth discussions with agreed medication actions to be 
enacted in the intervention group. The proportion of those 
not actioned, however, did not significantly decrease with the 
presence of a PTWR pharmacist in the intervention group. 
This highlights further opportunity to optimise medications 
though appropriate documentation of the medication plan 
during the PTWR, improved handover from the PTWR 
pharmacist and follow up by, the ward based pharmacist to 
ensure agreed decisions are actioned.
In comparison to the previous work in this area [2], there 
was no significant difference found in the change in number 
Table 3  Medication 
appropriateness
Statistical tests: * Chi squared, † student’s T-test
Comparator 
group (N = 130)
Intervention 
group (N = 130)
p Value
Patients with improvement in overall medication appropri-
ateness—n (%)
33 (25%) 48 (37%) 0.004*
Medication appropriateness—mean ± SD
Admission
START 0.94 ± 1.16 1.08 ± 1.23
STOPP 0.95 ± 1.02 0.78 ± 0.90
Overall START/STOPP 1.89 ± 1.58 1.85 ± 1.56
Discharge
START 0.85 ± 1.06 0.85 ± 1.12
STOPP 0.75 ± 0.83 0.56 ± 0.81
Overall START/STOPP 1.59 ± 1.39 1.42 ± 1.43
Difference overall START/STOPP admission to discharge 0.30 ± 0.87 0.43 ± 0.88 0.049
Table 4  Patient and service delivery related outcomes
Statistical tests: * Chi squared, † student’s T-test
Compara-
tor group 
(N = 130)
Interven-
tion group 
(N = 130)
p Value
Duration of the PTWR (e.g., time spent by PTWR team by with each patient) (mean, SD) minutes 23.8 ± 8.9 20.7 ± 9.9 < 0.008†
Ward pharmacist review (minimum of one pharmacy review by ward pharmacist during stay) 116 (89.2%) 108 (83%) 0.26*
Medication action plan (MAP) completed by pharmacist during admission 112 (86.2%) 104 (80%) 0.29*
Length of stay (days) Median (IQR) 4 (2–7) 4 (2–7) 0.34†
Discharge medication record (DMR) prepared for patient and patient counselled by clinical pharma-
cist
80 (62%) 73 (56.2%) 0.34*
Unplanned readmission < 30 days 15 (11.5%) 11 (8.5%) 0.43*
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of medications in the two groups from admission to dis-
charge. However, we demonstrated an overall improvement 
in medication appropriateness which may indicate that any 
reduction in inappropriately prescribed medication was 
offset by an increase in medication that was not previously 
prescribed, but should have been.
We believe that our study results are generalizable to 
similar general medical units for various reasons. Firstly, the 
clinical pharmacists involved in the PTWRs required well-
developed clinical knowledge, communication and interper-
sonal skills in order to actively engage in the ward round [6] 
and hence a minimum level of experience and competency 
was defined for the pharmacists attending PTWRs. It was felt 
that this level of experience would allow individuals to think 
proactively in the fast paced environment, hold a high level 
of clinical reasoning and develop good working relation-
ships with medical staff. We believe that using four differ-
ent pharmacists, with this minimum skill set, improves the 
generalisability of our results which has not previously been 
achieved in studies of this type [2]. According to coding 
data, it was felt that the study cohort was representative of a 
normal general medicine cohort. Lastly, patients under the 
care of all eight of the hospitals internal medical teams were 
included in both phases of this study and observations of all 
levels of medical staff as part of those teams was undertaken.
Limitations
Evidence from controlled studies demonstrates enhanced 
medication liaison reduces unplanned admissions to hospi-
tal [10]. In our study, a significant limitation was that close 
to 40% (153/260) of all patients across the comparator and 
intervention groups did not receive a pharmacist generated 
DMR when they left the hospital to guide them and their 
primary care team in the continuation of what was, for the 
intervention group, a significantly more appropriate medi-
cation regime at the time of discharge. This highlights a 
significant gap in medication handover between the hospital 
and primary care team with a high risk that some improve-
ments in medication appropriateness made were not handed 
over to the patient or their general practitioner on discharge.
A further limitation of this study is that the comparator 
and intervention observations were not carried out at the 
same time of the year and therefore other changes within the 
hospital, such as staff changes due to junior doctor rotations, 
may have impacted on outcomes. However, the observation 
periods were chosen to minimize this limitation with a six-
week gap in between to reduce compounding factors.
In addition, the lead researcher was not completely inde-
pendent. Observation bias was minimised by having the 
same observer recording data for both the comparator and 
intervention groups using a standardized data collection 
method and tool.
Our study did not demonstrate any statistically signifi-
cant changes in patient and Service Delivery Related Out-
comes (e.g., length of stay, unplanned readmissions), we 
did not collect data related to mortality and follow up was 
short (30 days). However, our study was not powered to 
detect differences in these outcomes. The results of this 
study could be used to estimate a sample size for a larger, 
more definitive trial.
At the time of study observation, the current START/
STOPP tool Version 1 was applied. Since observation 
completion, an updated version 2 of the START/STOPP 
criteria has been published. Of note, version 2 of START/
STOPP, with 114 criteria, represents a 31% increase in 
the total number of criteria included in version 1. The 
improvements found in medication appropriateness in our 
study as measured by the START/STOPP criteria version 
1 may therefore be an underestimation of those found if 
the updated criteria were applied.
Implication on practice and future research
This paper focuses on medication communication and 
appropriateness outcomes for patients and its findings have 
potential impacts on patients, professionals and the health 
care system. The findings demonstrate that interdiscipli-
nary input to decision making can improve the appropri-
ateness of medications for patients and outline the scope 
for clinical pharmacist input to improve collaborative 
optimisation of medication use and ensure that decisions 
made by medical staff around medication prescribing are 
handed over, followed through and enacted. This model 
of care ensures the appropriate use of health professional 
skill mix by ensuring Pharmacists are used at the optimal 
time for patient care input.
The cost of medication errors and inappropriate medi-
cations is high and the findings of improvement in medi-
cation appropriateness and communication in this study 
warrant further economic evaluation to assess whether a 
PTWR pharmacist service is cost-effective and possibly 
cost saving to the health system.
Conclusion
Clinical pharmacist participation on the PTWR leads to an 
increased level of medication-related communication and 
discussions targeted at high-risk medications, increased 
opportunity for collaborative decision making and improved 
medication appropriateness for patients and is therefore is 
a worthwhile endeavour. This provides further evidence on 
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this alternative model of service delivery that is consistent 
with benefits seen in other studies in this area.
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